Formatech provides contract development services for pharmaceutical companies, including cell culture and fermentation, pre-formulation, dosage form, and purification development services. Its dosage forms include liquid, controlled release, tablets, capsules as well as topicals, such as gels, ointments, and creams. It also provides project management services to its contract development customers. The company also offers manufacturing services, such as aseptic fill, finishing, and lyophilization. Formatech's specializations include small molecules, vaccines, and monoclonal antibodies.

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the central nervous system (CNS). The Company’s marketed product, Zanaflex Capsules, is approved by the United States Food and Drug Administration (FDA) for the management of spasticity. The Company’s product candidate Fampridine-SR, has completed two positive Phase III clinical trials for the improvement of walking ability in patients with MS. The research and development programs for the Company include Remyelination Programs and Chondroitinase Program.

GE Healthcare Medical Diagnostics helps your doctor to see right through you. The division, formerly Amersham plc, is one of the world's top producers of contrast-imaging agents and nuclear medicine agents used to enhance image quality in X-ray, magnetic resonance imaging, and ultrasound procedures. General Electric formed the division when it acquired Amersham and placed under its GE Healthcare umbrella. The former Amersham bioscience operations, which makes purification systems that allow for the development of more effective drugs through protein analysis, DNA sequencing, and genetic variation, is part of the GE Healthcare Life Sciences division.

Adamis Pharmaceuticals Corporation company was founded in 2006 and is based in Del Mar, California. Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company’s wholly owned subsidiary, Biosyn, Inc. has a portfolio of product candidates known as microbicides. Biosyn’s product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally. Biosyn’s product candidates include Savvy, which underwent Phase III clinical trials in Ghana and Nigeria for reduction in the transmission of human immunodeficiency virus/acquired immunodeficiency disease, (HIV/AIDS). Effective April 1, 2009, Cellegy Pharmaceuticals, Inc. merged with Adamis Pharmaceuticals Corporation, pursuant to which Adamis Pharmaceuticals Corporation (Adamis) became a wholly owned subsidiary of the Company.

MDRNA, Inc. company was founded in 1983 and is headquartered in Bothell, Washington. MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The company seeks to improve human health by combining RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide therapeutic options. MDRNA's multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology, and bioinformatics. The company is applying this expertise to a single, integrated drug discovery platform that would be the engine for its clinical pipeline and a versatile platform for establishing therapeutic partnerships. MDRNA is also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that might lead to safer and more effective RNAi-based therapeutics. The company combines expertise in siRNA science with proven delivery platforms and a growing IP portfolio, positioning MDRNA as an RNAi therapeutics company and a value-added collaborator for its research partners.

Affymax, Inc. company was founded in 2001 and is based in Palo Alto, California. Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The company’s lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide.

Semafore Pharmaceuticals is signaling its arrival on the oncology drug making scene. The development-stage drug discovery company is targeting the PI3K cell signaling pathways to create anti-cancer drugs. Its PI3K Inhibitors induce the death of cancerous cells in the treatment of tumors and could potentially treat brain, lung, and hematological cancers. Once administered, its lead candidate SF1126 attacks proteins expressed in tumors, but ignores healthy cells. Semafore has brought on a consulting firm to help shepherd SF1126 through its next stage of development.

Genfit SA, a biopharmaceutical company, develops therapies to reduce the cardiometabolic risk. The company focuses on the discovery and development of new chemical entities treating mainly dyslipidemia, atherosclerosis, diabetes, obesity, and inflammatory disorders. It has five programs in clinical phase of which, two are internal projects. The company’s internal projects consist of GFT14 that aims to target one of the major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated for atherogenic dyslipidemia for a patient who is overweight with or without diabetes. It develops its own drug candidates up to human proof of concept (Phase IIa). Genfit’s pipeline has various modes of action implying multimodal drugs and selective nuclear receptor modulation (SNuRM). The company also establishes partnerships with pharma groups on early-stage drug discovery programs. Its pharma alliances include Merck, Sanofi-Aventis, Solvay, Servier, and Pierre Fabre. Genfit was founded in 1999 and is headquartered in Loos, France with an additional office in Cambridge, the United States.

IBEX Technologies Inc. company develops and sells a series of proprietary enzymes for use in pharmaceutical research, particularly for arthritis and oncology. It markets diagnostic assays for use in arthritis tests that monitor the deterioration of cartilage; other assays monitor the rebuilding of cartilage. IBEX also provides enzymes for use as reagents used in hemostasis monitoring devices (for blood coagulation detection during certain surgical procedures). The majority of the company's sales are in the US (50%), followed by Europe and Canada, where sales revenues are split evenly. The publicly-traded company, founded in 1972, is led by CEO Paul Baehr.

Kreatech Biotechnology company develops tools used by pharmaceutical companies and medical researchers to detect and label RNA, DNA, and proteins. Its labeling kits, DNA probes, and other products are used in applications such as drug development and the diagnosis of disease. The company's investors include 3i Group, Alafi Capital, and Life Sciences Partners. Kreatech has formed alliances with many pharmaceutical and instrumentation firms, including heavyweights such as GE Healthcare Bio-Sciences and PerkinElmer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.